文献速递老年精神心境障碍

(-)-P7C3-S243可保护阿尔茨海默病大鼠模型免受神经精神缺陷和神经变性,而不改变淀粉样蛋白沉积或反应性胶质细胞

(-)-P7C3-S243 Protects a Rat Model of Alzheimer's Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia.
PubMed 文献 · Biol Psychiatry · 2017-11-06

该研究在雄性和雌性野生型及TgF344-AD大鼠中,从6月龄起每日给予(-)-P7C3-S243至9和18个月,评估认知与抑郁样行为及脑病理。结果显示该化合物安全地保护了衰老野生型和TgF344-AD大鼠免受认知缺陷和抑郁样行为,阻止了TgF344-AD大鼠的神经变性,且未改变淀粉样蛋白沉积或神经炎症指标。

要点

  • (-)-P7C3-S243在TgF344-AD大鼠中预防认知缺陷和抑郁样行为。
  • TgF344-AD大鼠的抑郁样行为早于认知缺陷出现。
  • 该治疗阻止神经变性但不改变淀粉样沉积或神经炎症。

核心结论

  • (-)-P7C3-S243可保护衰老野生型和TgF344-AD大鼠免受认知缺陷和抑郁样行为。
  • 该化合物阻止TgF344-AD大鼠的神经变性,但不改变淀粉样蛋白沉积或神经炎症指标。
  • 针对神经元细胞死亡的治疗策略可能适用于伴有认知缺陷和抑郁的AD患者。

研究设计与样本

  • 研究使用雄性和雌性野生型及TgF344-AD大鼠,从6月龄起每日给予(-)-P7C3-S243,持续9和18个月。
  • 在15和24月龄评估认知和抑郁相关行为表型,在24月龄评估脑病理和生物化学。

主要发现

  • (-)-P7C3-S243安全地保护衰老雄性和雌性野生型及TgF344-AD大鼠免受认知缺陷和抑郁样行为。
  • TgF344-AD大鼠的抑郁样行为早于认知缺陷出现,与许多AD患者表现一致。
  • (-)-P7C3-S243治疗阻止TgF344-AD大鼠的神经变性,而不改变淀粉样蛋白沉积或神经炎症指标。

临床怎么用

  • 提示针对神经元细胞死亡的P7C3类化合物可能成为AD相关认知缺陷与抑郁共病的新治疗方向。
  • 临床关注AD患者抑郁症状的早期识别,因其可能早于认知缺陷出现。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In addition to cognitive deficits, Alzheimer's disease (AD) is associated with other neuropsychiatric symptoms, including severe depression. Indeed, depression often precedes cognitive deficits in patients with AD. Unfortunately, the field has seen only minimal therapeutic advances, underscoring the critical need for new treatments. P7C3 aminopropyl carbazoles promote neuronal survival by enhancing nicotinamide adenine dinucleotide flux in injured neurons. Neuroprotection with P7C3 compounds has been demonstrated in preclinical models of neurodegeneration by virtue of promoting neuronal survival independently of early disease-specific pathology, resulting in protection from cognitive deficits and depressive-like behavior. We hypothesize that P7C3 compounds might be uniquely applicable to patients with AD, given the comorbid presentation of depression and cognitive deficits. METHODS: Aging male and female wild-type and TgF344-AD rats, a well-characterized preclinical AD model, were administered (-)-P7C3-S243 daily for 9 and 18 months, beginning at 6 months of age. Behavioral phenotypes related to cognition and depression were assessed at 15 and 24 months, and brain pathology and biochemistry were assessed at 24 months. RESULTS: (-)-P7C3-S243 safely protected aging male and female wild-type and TgF344-AD rats from cognitive deficits and depressive-like behavior. Depressive-like behavior occurred earlier than cognitive deficits in TgF344-AD rats, consistent with AD in many patients. Treatment with (-)-P7C3-S243 blocked neurodegeneration in TgF344-AD rats, without altering amyloid deposition or indicators of neuroinflammation. CONCLUSIONS: Neuronal cell death-specific treatment approaches, such as P7C3 compounds, may represent a new treatment approach for patients experiencing the combination of cognitive deficits and depression associated with AD.

来源:Biol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Voorhees JR, Remy MT, Cintrón-Pérez CJ, et al. (-)-P7C3-S243 Protects a Rat Model of Alzheimer's Disease From Neuropsychiatric Deficits and Neurodegeneration Without Altering Amyloid Deposition or Reactive Glia. Biol Psychiatry. 2017. PMID: 29246437. doi:10.1016/j.biopsych.2017.10.023

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。